Summarized by Masters of Longevity from PR Newswire.
A Phase 3 bladder cancer trial succeeded while a lung BLA was rejected and a Phase 2 dermatology trial failed.

Key Takeaways
- Cretostimogene trial was reported to reduce recurrence risk by 68%.
- FDA rejected the lung cancer BLA due to no OS statistical improvement.
- The anti-TSLP antibody trial failed despite clear target engagement.



